These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17568025)

  • 41. [Treatment of anaemia in medical oncology].
    Kullmann T; Culine S
    Orv Hetil; 2012 Jun; 153(25):973-7. PubMed ID: 22714031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
    Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
    JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is anemia of cancer different from chemotherapy-induced anemia?
    Steensma DP
    J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523
    [No Abstract]   [Full Text] [Related]  

  • 46. Erythropoiesis-stimulating agents--time for a reevaluation.
    Unger EF; Thompson AM; Blank MJ; Temple R
    N Engl J Med; 2010 Jan; 362(3):189-92. PubMed ID: 20054037
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
    Ofsthun NJ; Lazarus JM
    Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 49. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Waltzman RJ
    Cancer; 2004 Apr; 100(7):1545-6; author reply 1546. PubMed ID: 15042691
    [No Abstract]   [Full Text] [Related]  

  • 50. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
    Killian AD; Gupta V; Goetz AE
    Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
    Pujade-Lauraine E; Topham C
    Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amgen's point of view on epoetins.
    Seidenberg B; Perlmutter RM
    Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950
    [No Abstract]   [Full Text] [Related]  

  • 54. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Bohlius J; Engert A; Schwarzer G
    JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
    [No Abstract]   [Full Text] [Related]  

  • 55. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Darbepoetin alfa and chronic kidney disease.
    Minnerup J; Schäbitz WR
    N Engl J Med; 2010 Feb; 362(7):653-4; author reply 655. PubMed ID: 20187258
    [No Abstract]   [Full Text] [Related]  

  • 58. Epoetin: for better or for worse?
    Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601
    [No Abstract]   [Full Text] [Related]  

  • 59. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
    Steensma DP
    Am J Hematol; 2009 Jan; 84(1):3-5. PubMed ID: 19037863
    [No Abstract]   [Full Text] [Related]  

  • 60. Darbepoetin alfa and history of thromboembolic events.
    Ferretti G; Felici A; Cognetti F
    J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.